37813-30-2

Usage

Uses

Used in Organic Synthesis:
1-tert-butoxycarbonyl-4-hydroxy-L-proline ethyl ester is used as a building block in organic synthesis for the creation of complex organic molecules. The protective Boc group allows for selective reactions, enabling chemists to construct intricate molecular structures with precision and control.
Used in Peptide Chemistry:
In peptide chemistry, 1-tert-butoxycarbonyl-4-hydroxy-L-proline ethyl ester is used as a protected amino acid for the synthesis of peptides. The Boc group protects the hydroxy and amino groups during peptide bond formation, preventing unwanted side reactions and ensuring the correct sequence of amino acids in the final peptide product.
Used in Pharmaceutical Industry:
1-tert-butoxycarbonyl-4-hydroxy-L-proline ethyl ester is used as an intermediate in the synthesis of pharmaceutical compounds. Its ability to participate in selective reactions and form stable peptide bonds makes it a valuable component in the development of new drugs and therapeutic agents.
Used in Research and Development:
In the field of research and development, 1-tert-butoxycarbonyl-4-hydroxy-L-proline ethyl ester is used as a model compound to study the properties and reactivity of proline derivatives. Its unique structure and protective groups provide insights into the behavior of amino acids and their derivatives in various chemical reactions and biological processes.

Upstream product

• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 33996-30-4 trans-4-hydroxy-L-proline ethyl ester hydrochloride 
• 41840-28-2 S-tert-butoxycarbonyl-4,6-dimethyl-2-mercaptopyrimidine 
• 61478-25-9 (2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid ethyl ester 
• 64-17-5 ethanol 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 74-96-4 ethyl bromide 
• 51-35-4 4R-4-hydroxyproline 
• 75-03-6 ethyl iodide 

Downstream Products

• 74929-92-3 C₃₄H₃₅⁽²⁾H₂NO₂P₂ 
• 847978-71-6 (2S,4S)-4-(4-Nitro-benzoyloxy)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 61478-27-1 (2S,4S)-N-(tert-butoxycarbonyl)-4-(p-toluenesulfonyloxy)-2-<(p-toluenesulfonyloxy)methyl>pyrrolidine 
• 61478-28-2 (2S,4S)-N-butoxycarbonyl-4-diphenylphosphino-2-diphenylphosphinomethylpyrrolidine 
• 73300-49-9 N-Acryloyl-(2S,4S)-4-(diphenylphosphino)-2-<(diphenylphosphino)methyl>pyrrolidine 
• 61478-29-3 (2S,4S)-4-(diphenylphosphino)-2-[(diphenylphosphino)methyl]pyrrolidine 
• 215918-51-7 (2S,4R)-4-benzyloxy-2-methoxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 109953-95-9 tert-butyl (2S,4R)-4-(benzyloxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 191280-88-3 (2S,4S)-tert-butyl 4-hydroxy-2-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 1338549-49-7 (2S,4S)-2-(N₃-benzoylthymine-1-ylmethyl)-4-carboxymethoxy-pyrrolidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester 

Relevant academic research and scientific papers

Rational Drug Design of Topically Administered Caspase 1 Inhibitors for the Treatment of Inflammatory Acne

The use of an interleukin β antibody is currently being investigated in the clinic for the treatment of acne, a dermatological disorder affecting 650M persons globally. Inhibiting the protease responsible for the cleavage of inactive pro-IL1β into active IL-1β, caspase-1, could be an alternative small molecule approach. This report describes the discovery of uracil 20, a potent (38 nM in THP1 cells assay) caspase-1 inhibitor for the topical treatment of inflammatory acne. The uracil series was designed according to a published caspase-1 pharmacophore model involving a reactive warhead in P1 for covalent reversible inhibition and an aryl moiety in P4 for selectivity against the apoptotic caspases. Reversibility was assessed in an enzymatic dilution assay or by using different substrate concentrations. In addition to classical structure-activity-relationship exploration, topical administration challenges such as phototoxicity, organic and aqueous solubility, chemical stability in solution, and skin metabolic stability are discussed and successfully resolved.

Amino 6-membered ring derivative and pharmaceutical applications thereof including the use for manufacturing dipeptidyl peptidase-4(IDPP-IV) inhibitor

The present invention relates to an amino 6-membered ring derivative and pharmaceutical applications thereof, which specifically relates to the amino 6-membered ring derivative represented by the general formula (I) or stereoisomers thereof, pharmaceutically acceptable salts thereof, a prodrug, a pharmaceutical composition comprising the derivative, and the pharmaceutical use for manufacturing dipeptidyl peptidase-4(IDPP-IV) inhibitor, wherein the definition of each substituent in the general formula (I) is the same as described in the specification.

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

A short diastereoselective synthesis of cis-(2S,4S) and cis-(2R,4R)-4-hydroxyprolines

A concise synthesis of (2R,4R)-4-hydroxyproline (1) and (2S,4S)-4-hydroxyproline (2) has been developed in enantiomerically pure form from commercially available starting materials with excellent diastereoselectivity. The tightly bound chelation controlled transition state formed during the 5-exo-tet ring closure reaction is assumed to be the origin of high diastereoselectivity.

HYDROGEN CHLORIDE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND AND A PROCESS FOR THE PRODUCTION THEREOF

The present invention relates to the compound of the Formula I: and to methods of treating upper and lower obstructive airway diseases using said compound, to formulations comprising it, and to a particular crystalline form and processes of synthesis of the crystalline form. IM=105109

Design and stereoselective synthesis of four peptide nucleic acid monomers with cyclic structures in backbone

Four isomers of the monomer of peptide nucleic acid (PNA) were derived from (2S,4R)-4-hydroxyproline; they had different stereochemistries at the C 2 and C4 positions in the pyrrolidine ring. These different backbone conformations corresponding to four different stereochemistries were realized through a combination of inversions at the C2 and the C4 positions in pyrrolidine ring. The obtained backbone frameworks were reacted with N-benzoyl thymine to give the corresponding PNA monomers. Spectroscopic comparison of the resultant monomers confirmed their stereochemistries.

Heck reaction on morita-baylis-hillman adducts: Diastereoselective synthesis of pyrrolizidinones and pyrrolizidines

An efficient approach to the diastereoselective synthesis of benzylidene-, benzyl-pyrrolizidinones, and pyrrolizidines is described. The sequence is based on a highly stereoselective Heck reaction between a hydroxylated pyrrolizidinone, prepared from a Morita-Baylis-Hillman adduct, and a suitable aryl halide, using Nájeras oxime derived palladacycle as catalyst. Georg Thieme Verlag Stuttgart - New York.

Evidence for a stereoelectronic effect in human oxygen sensing

How PHDs achieve specificity: trans-4-prolyl hydroxylation of the transcription factor HIF occurs with stereochemical retention. Substrate-analogue studies show how the von Hippel Lindau tumor suppressor protein (pVHL) and the oxygen-sensing hydroxylases (PHDs) achieve specificity for hydroxy prolyl/prolyl residues for the C4-exo/endo prolyl conformations, respectively.

XINAFOATE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND

The present invention relates to the compound of the formula (I). To methods of treating upper and lower obstructive airway diseases using said compound, to formulations comprising it, and to polymorphs and processes of synthesis of the polymorphic forms.

Synthesis of a novel pyrrolidine-based peptide nucleic acid that contains tertiary amines in the main chain and its internalization into cells

A novel thymine monomer of pyrrolidine-based peptide nucleic acid that contains tertiary amines in the main chain (pyrrolidine-based amino peptide nucleic acid = PAPNA) was synthesized. A mixed oligomer of two PAPNA(T) units and seven units of pyrrolidine-based oxypeptide nucleic acid (POPNA), was synthesized by a solid-phase method. The mixed oligomer was internalized into CHO cells more readily than the previous version of POPNA oligomers. Copyright